Acquired amphotericin B resistance attributed to a mutated ERG3 in Candidozyma auris
Antimicrobial Agents and Chemotherapy · 05.11.2025 · 69 (11)
DOI: 10.1128/aac.00601-25 ↗Kurz gefasst
Fallbericht in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.11.2025. Verfasst von Lauryn Massic und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nevada State Public Health Laboratory, Reno, Nevada, USA. Hauptthemen laut MEDLINE: Amphotericin B, Antifungal Agents, Drug Resistance, Fungal, Fungal Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, CDC HHS, NCI NIH HHS.
Abstract (Originalsprache)
First identified in 2009, Candidozyma auris (formerly Candida auris ) is an emerging multidrug-resistant fungus that can cause invasive infections with a crude mortality rate ranging from 30 to 60%. Currently, 30–50% of C. auris isolates are intrinsically resistant to amphotericin B. In this study, we characterized a clinical case of acquired amphotericin B resistance using whole-genome sequencing, a large-scale phenotypic screen, comprehensive sterol profiling, and genotypic reversion using CRISPR. Data obtained in this study provide evidence that a deletion resulting in a frameshift in ERG3 significantly contributes to the observed resistant phenotype, and a nonsense mutation in ERG4 may more modestly contribute to resistance. Characterization of this isolate also revealed that a fitness cost is associated with the abrogation of ergosterol production and its replacement with other late-stage sterols. This article presents a clinical case description of amphotericin B resistance from a frameshift mutation in ERG3 in C. auris and marks an advancement in the understanding of antifungal resistance in this fungal pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nevada State Public Health Laboratory, Reno, Nevada, USA.
- University of Nevada Reno School of Medicine, Reno, Nevada, USA.
- St Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Washington State Department of Health, Olympia, Washington, USA.
- Brown University Division of Biology and Medicine, Providence, Rhode Island, USA.
- Broad Institute, Cambridge, Massachusetts, USA.
ORCID-Profile: Lauryn Massic, Laura A Doorley, Philip Dykema, P David Rogers, Josie E Parker, Steven L Kelly, Jeffrey M Rybak, Mark Pandori
Förderung
- NIAID NIH HHS
- CDC HHS
- NCI NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Centers for Disease Control and Prevention
- National Cancer Institute
Zitieren
APA
Massic, L., Doorley, L. A., Jones, S. J., Richardson, I., Siao, D. D., Siao, L., Dykema, P., Hua, C., Schneider, E., Cuomo, C. A., Rogers, P. D., Van Hooser, S., Parker, J. E., Kelly, S. L., Hess, D., Rybak, J. M., & Pandori, M. (2025). Acquired amphotericin B resistance attributed to a mutated ERG3 in Candidozyma auris. Antimicrobial Agents and Chemotherapy, 69(11). https://doi.org/10.1128/aac.00601-25
Vancouver
Massic L, Doorley LA, Jones SJ, Richardson I, Siao DD, Siao L, et al. Acquired amphotericin B resistance attributed to a mutated ERG3 in Candidozyma auris. Antimicrobial Agents and Chemotherapy. 2025;69(11). doi:10.1128/aac.00601-25
BibTeX
@article{Massic2025,
author = {Massic, Lauryn and Doorley, Laura A and Jones, Sarah J and Richardson, Irene and Siao, Danielle Denise and Siao, Lauren and Dykema, Philip and Hua, Chi and Schneider, Emily and Cuomo, Christina A and Rogers, P David and Van Hooser, Stephanie and Parker, Josie E and Kelly, Steven L and Hess, David and Rybak, Jeffrey M and Pandori, Mark},
title = {Acquired amphotericin B resistance attributed to a mutated ERG3 in Candidozyma auris},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {11},
doi = {10.1128/aac.00601-25}
}
EUVIMED